Role of hypoxia-inducible factor-1 in hypoxia-induced ischemic tolerance in neonatal rat brain

被引:1
|
作者
Bergeron, M
Gidday, JM
Yu, AY
Semenza, GL
Ferriero, DM
Sharp, FR
机构
[1] Univ Cincinnati, Vontz Ctr, Dept Neurol, Cincinnati, OH 45267 USA
[2] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA
[4] Washington Univ, Dept Neurosurg, St Louis, MO USA
[5] Johns Hopkins Univ, Sch Med, Inst Med Genet, Dept Pediat, Baltimore, MD USA
[6] Johns Hopkins Univ, Sch Med, Inst Med Genet, Dept Med, Baltimore, MD USA
关键词
D O I
10.1002/1531-8249(200009)48:3<285::AID-ANA2>3.0.CO;2-8
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Hypoxia-inducible factor-1 (HIF-1) is a heterodimer composed of HIF-1 alpha and HIF-1 beta protein subunits. This transcription factor is essential for the activation of hypoxia-inducible genes like erythropoietin, some glucose transporters, the glycolytic enzymes, and vascular endothelial growth factor. Because HIF-1 activation may promote cell survival in hypoxic tissues, we studied the effect of hypoxic preconditioning on HIF-1 expression in neonatal rat brain. Hypoxic preconditioning (8% O-2 for 3 hours), a treatment known to protect the newborn rat brain against hypoxic-ischemic injury, markedly increased HIF-1 alpha and HIF-1 beta expression. To support the role of HIF-1 in protective preconditioning, we also studied the effect of two other known HIF-1 inducers, cobalt chloride (CoCl2) and desferrioxamine (DFX), on HIF-1 expression and neuroprotection in newborn brain. HIF-1 alpha and HIF-1 beta protein levels were markedly increased after intraperitoneal injection of CoCl2 (60 mg/kg) and moderately increased after intraperitoneal injection of DDC (200 mg/kg) 1 to 3 hours after the injections. Preconditioning with CoCl2 or DFX 24 hours before hypoxia-ischemia afforded 75 and 56% brain protection, respectively, compared with that in vehicle-injected littermate controls. Thus, HIF-1 activation could contribute to protective brain preconditioning, which could be used in high-risk deliveries and other clinical situations.
引用
收藏
页码:285 / 296
页数:12
相关论文
共 50 条
  • [41] Role Hypoxia-inducible Factor-1α in the Development of Liver Fibrosis
    Copple, Bryan L.
    Moon, Jeon-Ok
    FASEB JOURNAL, 2008, 22
  • [42] The Role of Hypoxia-Inducible Factor-1 Alpha in Renal Disease
    Liu, Huixia
    Li, Yujuan
    Xiong, Jing
    MOLECULES, 2022, 27 (21):
  • [43] Role of hypoxia-inducible factor-1α as a cancer therapy target
    Patiar, Shalini
    Harris, Adrian L.
    ENDOCRINE-RELATED CANCER, 2006, 13 : S61 - S75
  • [44] The role of hypoxia-inducible factor-1 alpha in TEMPI syndrome
    Khan, Sujoy
    CLINICAL KIDNEY JOURNAL, 2011, 4 (06): : 454 - +
  • [45] Activation of hypoxia-inducible factor-1 in rat brain after perinatal anoxia: role of body temperature
    Kletkiewicz, Hanna
    Hyjek, Malwina
    Jaworski, Krzysztof
    Nowakowska, Anna
    Rogalska, Justyna
    INTERNATIONAL JOURNAL OF HYPERTHERMIA, 2018, 34 (06) : 824 - 833
  • [46] Hypoxia-Induced Mitogenic Factor Promotes Cardiac Hypertrophy via Calcium-Dependent and Hypoxia-Inducible Factor-1 Mechanisms
    Kumar, Santosh
    Wang, Gang
    Liu, Wenjuan
    Ding, Wenwen
    Dong, Ming
    Zheng, Na
    Ye, Hongyu
    Liu, Jie
    HYPERTENSION, 2018, 72 (02) : 331 - 342
  • [47] ROLE OF ENDOTHELIAL HYPOXIA-INDUCIBLE FACTORS IN HYPOXIA-INDUCED PULMONARY VASOCONSTRICITON
    Gu, Y.
    Tang, H.
    Gardi, J. G.
    Yuan, J. X.
    Fraidenburg, D. R.
    Chen, J.
    Makino, A.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2016, 64 (04)
  • [48] Hypoxia-inducible factor-1 in tumour angiogenesis
    Yong-Hong Shi Wei-Gang Fang Department of Pathology
    World Journal of Gastroenterology, 2004, (08) : 1082 - 1087
  • [49] Hypoxia-inducible factor-1 and oncogenic signalling
    Bárdos, JI
    Athcroft, M
    BIOESSAYS, 2004, 26 (03) : 262 - 269
  • [50] Inhibitors of hypoxia-inducible factor-1 signaling
    Belozerov, Vladimir E.
    Van Meir, Erwin G.
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2006, 7 (12) : 1067 - 1076